News


Please see the below for our press releases, upcoming events and to follow our news:

Press releases

April 2018            TopiVert to Present TOP1630 clinical Proof-of-Concept data in Dry Eye Syndrome at the ARVO 2018 Annual Meeting

March 2018           TopiVert Publication Highlights the Potential of Narrow Spectrum Kinase Inhibitors in Dry Eye Disease 

January 2018       TopiVert announces positive Phase 1 study results with its oral formulation of TOP1288 for the treatment of ulcerative colitis 

November 2017       TopiVert demonstrates proof of concept in Phase 1/2a study of TOP1630 in the treatment of dry eye syndrome

June 2017                TopiVert completes three clinical studies for its two lead NSKI programmes in ulcerative colitis and dry eye syndrome 

February 2017         TopiVert commences Phase I study with oral TOP1288 in the treatment of ulcerative colitis 

                                 TopiVert commences proof of concept study for TOP1630 in the treatment of dry eye syndrome

November 2016      TopiVert receives IND approval for TOP1630 in the treatment of dry eye syndrome

October 2016          TopiVert doses first patients in TOP1288 Phase 2a POC study in ulcerative colitis

May 2016                TopiVert completes preclinical development with TOP1630 for dry eye disease 

                                 TopiVert to present First-In-Human data from its Phase I clinical study with TOP1288 at DDW 2016 in San Diego 

March 2016             TopiVert reports successful Phase I study with TOP1288 for the treatment of ulcerative colitis

                                  TopiVert to present First-In-Human data from its Phase I clinical study with TOP1288 at ECCO

May 2015                 Topivert starts Phase I Clinical Trial with lead compound, TOP1288, in Ulcerative Colitis

December 2011       £8 million funding for new start-up TopiVert

upcoming Events

TopiVert will be attending a number of industry and medical conferences throughout 2018. 

 

Digestive Disease Week (DDW) 2018 Annual Meeting taking place June 2-5 2018 in Washington, DC

TopiVert will be presenting a clinical abstract “A novel Phase I trial design to evaluate safety, tolerability, pharmacokinetics and pharmacodynamics of TOP1288, a narrow spectrum kinase inhibitor, delivered topically to the colon via oral administration”. The details of the poster presentation are as follows:

Session title: 

Title: A novel Phase I trial design to evaluate safety, tolerability, pharmacokinetics and pharmacodynamics of TOP1288, a narrow spectrum kinase inhibitor, delivered topically to the colon via oral administration

Authors: Adele Rowley et al.

Abstract number: 

Date/Time/Location: Saturday 2 June 2018/12:00PM–2:00PM/Hall C

Follow our news

Please enter your email address in the news alerts entry box in the footer below if you would like to receive news updates from TopiVert. You can also follow us on Twitter at #topivert and also our thread #nski